0

ALK-Abello AS (ALK B) – Financial and Strategic SWOT Analysis Review

Publisher Name :
Date: 15-Mar-2017
No. of pages: 48

ALK-Abello AS (ALK B) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ALK-Abello A/S (ALK) is a research-oriented pharmaceutical company, which discovers, develops and commercializes immunotherapies for allergy prevention and treatment. It also markets diagnostics and other services to allergy clinics. The company’s allergy immunotherapy product portfolio includes tablet-based vaccines, sublingual or drop-based vaccines, subcutaneous vaccines; and adrenaline auto-injector to treat severe allergic reactions in emergencies (anaphylaxis). ALK’s research and development pipeline products include sublingual immunotherapy tablets for addressing the ragweed, house dust mite and tree pollen allergy. The company’s products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, dog, venom and cat, among others. It has subsidiaries in Europe, North America, Asia-Pacific and other international markets. ALK is headquartered in Horsholm, Denmark.

ALK-Abello AS Key Recent Developments

Mar 03, 2017: ALK Appoints SVP of R&D for North America and International Markets
Feb 07, 2017: ALK releases its annual report 2016
Jan 10, 2017: Carsten Hellmann joins ALK as new President and CEO
Jan 04, 2017: ALK upgrades its full-year 2016 financial outlook following better than expected Q4 sales
Nov 10, 2016: ALK-Abello: Nine-month interim report (Q3) 2016

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of content
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
ALK-Abello A/S - Key Facts 6
ALK-Abello A/S - Key Employees 7
ALK-Abello A/S - Key Employee Biographies 8
ALK-Abello A/S - Major Products and Services 9
ALK-Abello A/S - Pharmaceutical Pipeline Products Data 10
ALK-Abello A/S, Pipeline Products by Therapy Area 10
ALK-Abello A/S, Pipeline Products by Development Phase 11
ALK-Abello A/S - History 12
ALK-Abello A/S - Company Statement 15
ALK-Abello A/S - Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Section 2 - Company Analysis 18
ALK-Abello A/S - Business Description 18
ALK-Abello A/S - Corporate Strategy 19
ALK-Abello A/S - SWOT Analysis 20
SWOT Analysis - Overview 20
ALK-Abello A/S - Strengths 20
ALK-Abello A/S - Weaknesses 21
ALK-Abello A/S - Opportunities 22
ALK-Abello A/S - Threats 23
ALK-Abello A/S - Key Competitors 24
Section 3 - Company Financial Ratios 25
Financial Ratios - Capital Market Ratios 25
Financial Ratios - Annual Ratios 26
Performance Chart 28
Financial Performance 28
Financial Ratios - Interim Ratios 29
Financial Ratios - Ratio Charts 30
Section 4 - Company's Lifesciences Financial Deals and Alliances 31
ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32
ALK-Abello A/S, Recent Deals Summary 33
Section 5 - Company's Recent Developments 34
Mar 03, 2017: ALK Appoints SVP of R&D for North America and International Markets 34
Feb 07, 2017: ALK releases its annual report 2016 35
Jan 10, 2017: Carsten Hellmann joins ALK as new President and CEO 36
Jan 04, 2017: ALK upgrades its full-year 2016 financial outlook following better than expected Q4 sales 37
Nov 10, 2016: ALK-Abello: Nine-month interim report (Q3) 2016 38
Aug 16, 2016: ALK-Abello: Six-month interim report (Q2) 2016 39
May 17, 2016: ALK appoints Carsten Hellmann as new President and CEO 40
May 04, 2016: ALK-Abello: Three-month interim report 2016 41
Feb 22, 2016: ALK's CEO Jens Bager steps down 42
Feb 09, 2016: ALK releases its annual report 2015 43
Section 6 - Appendix 44
Methodology 44
Ratio Definitions 44
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
ALK-Abello A/S, Key Facts 6
ALK-Abello A/S, Key Employees 7
ALK-Abello A/S, Key Employee Biographies 8
ALK-Abello A/S, Major Products and Services 9
ALK-Abello A/S, Number of Pipeline Products by Therapy Area 10
ALK-Abello A/S, Number of Pipeline Products by Development Stage 11
ALK-Abello A/S, History 12
ALK-Abello A/S, Subsidiaries 16
ALK-Abello A/S, Key Competitors 24
ALK-Abello A/S, Ratios based on current share price 25
ALK-Abello A/S, Annual Ratios 26
ALK-Abello A/S (Cont...1), Annual Ratios 27
ALK-Abello A/S, Interim Ratios 29
ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32
ALK-Abello A/S, Recent Deals Summary 33
Currency Codes 44
Capital Market Ratios 44
Equity Ratios 45
Profitability Ratios 45
Cost Ratios 46
Liquidity Ratios 46
Leverage Ratios 46
Efficiency Ratios 47

List of Figures
ALK-Abello A/S, Pipeline Products by Therapy Area 10
ALK-Abello A/S, Pipeline Products by Development Phase 11
ALK-Abello A/S, Performance Chart (2012 - 2016) 28
ALK-Abello A/S, Ratio Charts 30
ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 32

News

  • Understanding the Need For Travel Vaccination
  • If you are getting ready for a particular trip that can see you away from your house for about a month or so, then it is necessary for you to take the help of travel vaccinations. Not ...
  • The Work Of The Ophthalmology Specialist
  • When we consider ophthalmology as a branch of science, it is actually about the treatment as well as getting to diagnose the different kinds of diseases and the disorder that is to ...
  • The Process Of Dental Implants And The Subsequent Recovery
  • In the United States of America, the fear of going to a dentist happens to rank number one on the list of children as well as adults. Most of the people are actually concerned when ...
  • The medication that can help the rural population
  • It is not always that you get to see world class hospitals in the rural areas, be it America or any other country. Hence, it is important that people actually take the help of tele-medication, ...
  • The Future of Telemedicine & Its Use
  • When talking about telemedicine, you do get to realize that it is the healthcare of the future. Most of the people do not realize the implications, and for more so the time, telemedicine ...

Get Updates

Share This Post

Recent Posts

© 2017 RnR Company Profiles. All rights reserved.